Generic Name and Formulations:
Varicella zoster vaccine, live, attenuated; minimum of 19,400 PFU/0.65mL dose; pwd for SC inj after reconstitution; contains porcine gelatin, neomycin and bovine serum (trace); preservative-free.
Merck & Co., Inc.
Indications for ZOSTAVAX:
Prevention of herpes zoster (shingles) in adults ≥50 years of age.
Limitations Of use:
Not for treating zoster or postherpetic neuralgia. Not for preventing primary varicella infection.
<50yrs: not recommended. ≥50yrs: one 0.65mL dose by SC inj once in upper arm. Administer immediately upon reconstitution.
Immunodeficiency (eg, HIV, leukemia, lymphoma, bone marrow or lymphatic cancer, immunosuppressive therapy). Pregnancy (during and 3 months after vaccination).
Have epinephrine inj (1:1000) available. Consider deferral in acute illness or acute untreated tuberculosis. May not protect 100% of recipients. Virus transmission may occur between recipients and susceptible contacts. Nursing mothers.
See Contraindications. Immunosuppressants may cause disseminated disease. Consider administration of Zostavax and Pneumovax 23 vaccines separated by ≥4 weeks. Concomitant inactivated influenza vaccines: see full labeling.
Inj site reactions (eg, erythema, pain, swelling, pruritus), headache; cardiovascular events.
To report adverse events, contact VAERS at (800) 822-7967.
Single-dose vials—1, 10 (w. diluent)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC